MissionIR Articles
-
MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Featured in Equity Research Report
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an equity research report by Maxim Group LLC. The piece discusses VistaGen’s…
-
MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Closes $100M Underwritten Public Offering
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of…
-
MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Commencement, Pricing of Underwritten Public Offering
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the commencement and pricing of an underwritten public offering. The offering consists of…
-
MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a…
-
MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
VistaGen Therapeutics (NASDAQ: VTGN) has appointed a new vice president of translational medicine. A pioneer in the development of neuroactive steroids known as pherines, Louis Monti, MD., PhD., developed the original scientific platform that enabled…
-
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment
VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos” Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such…
-
VistaGen Therapeutics (NASDAQ: VTGN) Seeks to Address Rising Incidence of Mental Health Disorders in United States
VistaGen currently developing three novel drug candidates designed to treat central nervous system disorders Anxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatment Prevalence…
-
MissionIRNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020.…
-
VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO Discusses ‘Game-Changing’ Potential of Drug Pipeline Lineup in Stock2Me Podcast
VTGN is committed to developing and commercializing differentiated new generation medications that go beyond the current standard of care for anxiety, depression and other CNS disorders. VTGN currently has three drugs in its pipeline, PH94B…
-
MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Reports Positive Preclinical Data on PH94B’s Mechanism of Action
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced new in vitro electrophysiology data. According to the update, the data demonstrate that…
-
VistaGen Therapeutics’ (NASDAQ: VTGN) New Generation Phase 3 Drug Candidate for Social Anxiety Disorder Gains Importance Amid FDA Wariness of Benzodiazepines
VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disorders PH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of…
-
MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Stock2Me Podcast
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to…
-
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder
Study results have exciting therapeutic potential across wide range of CNS indications. VTGN focused on developing new generation of medications to treat anxiety, depression and more. Company committed to finding treatment to help estimated 264…
-
MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in BioWorld Article
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends…
-
MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Research Report
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent research report by Aegis Capital Corp. The report…
-
MissionIRNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’
VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders.…
-
VistaGen Therapeutics Inc. (NASDAQ: VTGN) is “One to Watch”
VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders Two of the company’s drug candidates have received an FDA fast track designation, including for…
-
MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses ‘Sea of Change’ to Future of Anxiety Treatment
VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Life Science Leader titled, “The Future of Anxiety Treatment Will Be Drastically Different.” In the piece, Singh, an experienced professional who has dedicated…
-
MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety
VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety,…
-
MissionIRNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses PH94B Drug Candidate in Applied Clinical Trials Publication
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was recently featured in an Applied Clinical Trials article titled, “Pushing Late-Stage Treatments Forward…
Search Articles
Latest Articles
- A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Advancing Retail Innovation Through AI-Powered Smart-Cart Technology
- Forward Industries Inc. (NASDAQ: FWDI) Positive Update for Shareholders After Debuting the Company’s Solana Treasury Strategy
- Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures Funding to Strengthen North American Supply Chain
- MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast